Clinical Trial: Study Evaluating Safety & Tolerability of Migaldendranib With/Without Berahyaluronidase Alfa-pmph in Healthy Volunteers

U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07370155) titled 'Study Evaluating Safety & Tolerability of Migaldendranib With/Without Berahyaluronidase Alfa-pmph in Healthy Volunteers' on Jan. 19.

Brief Summary: This is a Phase 1, open-label, multiple-dose study to evaluate the safety, tolerability, and PK of MGB alone or in combination with ALT-B4 after weekly subQ MGB administration in up to 36 healthy volunteers at 1 site in Australia.

Study Start Date: Jan. 29

Study Type: INTERVENTIONAL

Condition: Healthy Volunteers

Intervention: DRUG: MGB 200 mg

Participants receive weekly subcutaneous administration of MGB

DRUG: MGB 400 mg

Participants receive an intermediate dose of MGB administe...